About Novasorb®
Novasorb® is a cationic emulsion developed to address the main challenges of topical ocular drug administration: absorption, drug solubility, patient compliance and high tolerability.
Our topical technology is based on electrostatic attraction that occurs between the droplets of a positively-charged emulsion loaded with active ingredient, and the eye mucus, and epitheliums including cornea and conjunctiva, which are all negatively charged.
Therefore, Novasorb® improves solubility and absorption of lipophilic drugs (40-60% of new chemical entities), reduces the number of instillations and side effects, leading to better efficacy and compliance.
This new technology paradigm applies for the treatment of a wide spectrum of ocular diseases such as dry eye, allergies, anterior uveitis, and glaucoma.
Eye surface
Spreading and lubrication are key issues in the treatment of ocular surface conditions.
The electrostatic attraction onto the negatively-charged surface of the eye allows the optimal spreading of the Novasorb® cationic emulsion and improves the drug absorption.
Contact angle and surface tension studies have demonstrated that Novasorb® cationic emulsions have a better spreading coefficient on the cornea and conjunctiva than conventional eye drops and anionic emulsions. This four-fold higher spreading coefficient (lower contact angle) leads to better wettability properties of the eye surface.
In addition, the lipidic content of the emulsion ensures lubrication and protection of the eye surface against mechanical damaging during blinking, as demonstrated in alkali burn and desepithelization models.
